Is Cyclerion Therapeutics Inc (CYCN) overvalued? · rev $2.0M
Cyclerion Therapeutics Inc (CYCN) is a biotechnology company listed on US.
This page asks whether Cyclerion Therapeutics Inc (CYCN) looks expensive on cached numbers — not a short thesis.
Latest reported CYCN revenue for 2024-12-31 was $2.0M. Net income was -$3.1M. CYCN currently screens at market cap $8.6M.
CYCN currently screens at market cap $8.6M. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next CYCN 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the CYCN stock page for the full model, not this heading.
Not investment advice.